Dealing with a cancer diagnosis can feel like you're caught in a whirlwind of treatments—appointments piling up, emotions ...

PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.

From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea.

Darcey Kemp, from Mobberley, had to undergo a full blood transfusion after doctors found she was battling juvenile ...

Johnson & Johnson's long-term prospects are promising due to strong drug pipeline developments and significant R&D ...

One of two of Opthea's phase III trials for a common eye disease has failed to meet its objectives, casting doubts on the ...

Below is a roundup of health tech and digital health news you may have missed | Keep up with some of the latest headlines in ...

McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability. Read why MCK stock is a ...

CheapInsurance.com examined the demographics of the uninsured population in the United States using data from the Census ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

Maybe you’re unfamiliar with him, or maybe you’ve heard he’s an up-and-coming comedian with a gift for prankish anti-bits. He ...

Bayer obtains an exclusive worldwide license for MTA-cooperative PRMT5 inhibitor from Suzhou Puhe BioPharma for selective ...